Related Parties - Additional Information (Detail) - USD ($)
|
|
1 Months Ended |
12 Months Ended |
|
Dec. 03, 2014 |
Sep. 30, 2014 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Jun. 30, 2012 |
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Net sales |
|
|
$ 0
|
$ 0
|
|
| IPO Stock purchased, value |
|
|
|
56,539,000
|
|
| Accrued expenses due to Intrexon |
|
|
$ 1,546,000
|
7,000
|
|
| Intrexon [Member] |
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Collaboration Agreement cancellation notification |
|
|
90 days
|
|
|
| Collaboration Agreement cancellation with material breach that cannot be remedied |
|
|
60 days
|
|
|
| Common stock to be purchased under equity purchase commitment |
|
$ 15,000,000
|
|
|
|
| Shares issued upon conversion |
918,206
|
|
|
|
|
| IPO Stock purchased, value |
$ 19,496,000
|
|
|
|
|
| IPO Stock purchased, shares |
1,772,364
|
|
|
|
|
| Accrued expenses due to Intrexon |
|
|
$ 1,546,000
|
|
|
| Intrexon [Member] | Investigational New Drug (IND) Filing Milestone Event [Member] |
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Milestone payable |
|
500,000
|
|
|
|
| Intrexon [Member] | IND Acceptance Milestone Event [Member] |
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Milestone payable |
|
2,500,000
|
|
|
|
| Intrexon [Member] | Phase III Milestone Event [Member] |
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Milestone payable |
|
3,000,000
|
|
|
|
| Intrexon [Member] | Approval Milestone Event [Member] |
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Milestone payable |
|
5,000,000
|
|
|
|
| Intrexon [Member] | Approval Amendment Milestone Event [Member] |
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Milestone payable |
|
1,000,000
|
|
|
|
| Intrexon [Member] | Cumulative Sales Milestones One [Member] |
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Milestone payable |
|
5,000,000
|
|
|
|
| Net sales |
|
300,000,000
|
|
|
|
| Intrexon [Member] | Cumulative Sales Milestones Two [Member] |
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Milestone payable |
|
7,500,000
|
|
|
|
| Net sales |
|
650,000,000
|
|
|
|
| Intrexon [Member] | Cumulative Sales Milestones Three [Member] |
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Milestone payable |
|
10,000,000
|
|
|
|
| Net sales |
|
1,000,000,000
|
|
|
|
| Intrexon [Member] | Promissory Note [Member] |
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Promissory note issued as up-front fee |
|
$ 10,000,000
|
|
|
|
| Shares issued upon conversion |
918,206
|
|
|
|
|
| Purpose, Co. [Member] |
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Reimbursement for development cost, amount |
|
|
|
|
$ 250,000
|
| Reimbursement for development cost, paid |
|
|
187,000
|
173,000
|
|
| Research and Development [Member] | Intrexon [Member] |
|
|
|
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
| Research and development expense from transaction with Intrexon |
|
|
$ 3,100,000
|
$ 14,000
|
|